Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation.
about
Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspectiveImmune Mechanisms in Myelodysplastic SyndromePD-1 expression conditions T cell avidity within an antigen-specific repertoire.Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy.Epigenetic DNA Demethylation Causes Inner Ear Stem Cell Differentiation into Hair Cell-Like CellsHypomethylating agents after allogeneic blood stem cell transplantation.The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation.A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions.Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacyEmerging biological therapies for the treatment of myelodysplastic syndromes.Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.Hypomethylating Agents as a Therapy for AML.Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.Dysregulation of Cell Death and Its Epigenetic Mechanisms in Systemic Lupus Erythematosus.Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms.Treatment of Relapsed/Refractory Acute Myeloid Leukemia.PD-1/PD-L1 inhibitors in haematological malignancies: update 2017.Treatment of Low-Blast Count AML using Hypomethylating Agents.Reduced potency of cytotoxic T lymphocytes from patients with high-risk myelodysplastic syndromes.Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer.Harness the synergy between targeted therapy and immunotherapy: what have we learned and where are we headed?NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-Lymphocyte Responses in Patients with Myelodysplastic Syndrome.PD1 and PDL1 upregulation and survival after decitabine treatment in lower risk MDS.Immunological effects of hypomethylating agents.Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation.Targeting the Immune Microenvironment in Acute Myeloid Leukemia: A Focus on T Cell Immunity.Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions.Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature.DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven ApproachImmuno-Oncology: Emerging Targets and Combination TherapiesNovel Strategies for Peptide-Based Vaccines in Hematological Malignancies
P2860
Q26744089-0411C70F-788C-4EE0-9D64-D04DBE87F729Q26744500-260137AB-D13B-488D-AD91-6088D7E5837CQ36597350-0ACB626A-CFFA-4370-9F14-3B0F2C8A8C35Q37022306-A919ADAA-58D1-4A07-AEA1-697EB0DD4445Q37147061-8FBCF5D9-C64B-4990-8543-2A2EF99088FCQ37531039-07C07EAD-855D-4C61-B873-19A78D5F3C39Q37731703-02D657B5-739F-4BF3-BCE2-206FA0B47B37Q38651923-3A003E78-05FC-48D2-B6CD-F3ED8DA43155Q38678113-EB0FCF0A-34FE-4B76-8810-D58A27F0CE09Q38749824-728996E8-3907-4777-B64A-01B48A95809DQ38834981-34AB9442-6C79-400D-AD35-2CA7335CBE9FQ38838643-A00CDF0B-1F16-4408-950D-6C06B1E3D0C7Q38911864-4CA7086E-FFC4-472D-BED2-4AC19C4EA1C7Q38961023-28B97C74-8BC1-4FD0-B880-6EFF0ECE5CE9Q39062993-98E5155E-0BC7-47B9-A4D6-66B300A99CAAQ39072004-D0C95D67-801F-446B-9C81-BE35D2F326D4Q39175665-17E5888E-E71A-4993-902E-EE087DD8CB67Q39420466-03313C49-21F8-40C3-A68D-35D295D4C883Q39429687-7C7C191D-C942-41F8-9B60-22F47EECD7F3Q40592382-A4FBF682-29DE-4A18-A001-628DE7AFD925Q46166592-1D5DC18C-8435-4145-8B1F-790880A03041Q47136084-76C36C2C-A6F6-41F8-956D-E3C467A2C4B1Q47923445-1947FA35-F871-460B-9C71-D72778A9940EQ48037303-0DFD5C2D-79C7-4EEC-AE33-56F6C836881AQ48229616-FBCCA0B8-2AE7-42A8-9801-5F721F076483Q49976405-ED039FA0-9512-42DD-B60B-D7E7E4C70DC0Q55299267-37AF4F23-E77E-4B7B-8305-0A0F86F2B3DBQ55354182-C0DC4EFB-B8D0-4A1F-A201-13B4D0AF099EQ55364989-657DFC37-AC49-4D7A-9F10-04137550A5C5Q55425717-11BF6405-9F4B-4CF4-BFED-0DBDACB78790Q56378931-A5BC4D17-2E7D-4A91-9A10-6B494D5FAD0BQ56889817-53BF74DD-0D44-42FD-86FC-C66F101E5F81Q57486479-731E9785-042A-4D31-8A96-0A45B768B239
P2860
Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Hypomethylation and up-regulat ...... g of PD-1 and DNA methylation.
@ast
Hypomethylation and up-regulat ...... g of PD-1 and DNA methylation.
@en
type
label
Hypomethylation and up-regulat ...... g of PD-1 and DNA methylation.
@ast
Hypomethylation and up-regulat ...... g of PD-1 and DNA methylation.
@en
prefLabel
Hypomethylation and up-regulat ...... g of PD-1 and DNA methylation.
@ast
Hypomethylation and up-regulat ...... g of PD-1 and DNA methylation.
@en
P2093
P2860
P356
P1433
P1476
Hypomethylation and up-regulat ...... g of PD-1 and DNA methylation.
@en
P2093
Anni Skovbo
Kirsten Grønbæk
Lone S Friis
Marianne B Treppendahl
Marianne Hokland
Mette S Holm
P2860
P304
P356
10.18632/ONCOTARGET.3324
P407
P577
2015-04-01T00:00:00Z